Biotech Share Sales in US Deliver Biggest Quarter Since 2021
Summarize this article with:
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the worldAmericas+1 212 318 2000EMEA+44 20 7330 7500Asia Pacific+65 6212 1000Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the worldAmericas+1 212 318 2000EMEA+44 20 7330 7500Asia Pacific+65 6212 1000US Stocks:US-listed biotechnology and pharmaceutical company share sales are staging a late-year revival, as mergers and acquisitions in the industry boost valuations and stoke additional demand.With more than $4.2 billion raised last week alone, sales of new and existing stock in publicly traded drug developers have jumped to $13.7 billion in the fourth quarter. That’s already the biggest quarterly haul since the first three months of 2021, according to data compiled by Bloomberg. The surge came even though there haven’t been any deals above $1 billion in the sector so far this quarter.